GSK's Blenrep Produces Significant Survival Improvement in Relapsed or Refractory Multiple Myeloma
February 6th 2024Patients with relapsed or refractory multiple myeloma administered Blenrep combined with bortezomib plus dexamethasone experienced a 59% reduction in the risk of disease progression or death compared with the standard of care.
FDA Fast Tracks Antibody-Drug Conjugate for Ovarian, Fallopian Tube, Primary Peritoneal Cancers
February 6th 2024BioNTech SE and Duality Biologics' next-generation antibody-drug conjugate is being evaluated for patients with platinum-resistant ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer previously administered one to three systemic treatment regimens.
Beyond Images: 2024 Trends Reshaping Healthcare with Radiopharmaceuticals
February 5th 2024By capitalizing on AI advancements, pushing the boundaries of personalized medicine with theranostics, and strengthening digital healthcare networks, radiopharmaceuticals are poised to transform healthcare from a reactive to a proactive discipline.
Sanofi Announces New Reservation Program to Mitigate Shortages of RSV Vaccine for Next Season
February 2nd 2024Beyfortus (nirsevimab-alip), a monoclonal antibody that protects against respiratory syncytial virus-associated lower respiratory tract disease, experienced higher than anticipated demand that led to shortages during the 2023-2024 season.
Astellas Announces Submission of sNDA for Padcev/Keytruda Combo for Urothelial Cancer
January 31st 2024Approval sought for Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) for the first-line treatment of adults with previously untreated locally advanced or metastatic urothelial cancer, which would be the first approved combination alternative to platinum-containing chemotherapy for this patient population.
FDA Approves Takeda's Gammagard Liquid for Chronic Inflammatory Demyelinating Polyneuropathy
January 30th 2024This is Takeda's second approval in chronic inflammatory demyelinating polyneuropathy this month after the FDA approved HyQvia to protect against relapse of neuromuscular disability and impairment in this patient population.